Abstract. The rK39 test is a serologic assay for the rapid diagnosis of visceral leishmaniasis (VL). Serum from a North American cohort of 59 otherwise asymptomatic soldiers with cutaneous leishmaniasis (CL) was tested with the rK39 dipstick and ELISA assays, and 10.2% and 28.8% had positive results, respectively. CL is associated with a reactive rK39 assay result in some patients without clinical evidence of VL.
INTRODUCTION
Visceral leishmaniasis (VL) is a significant health problem worldwide, with nearly 500,000 new cases occurring annually. 1 Rare in the United States, it has been reported primarily in travelers, immigrants from endemic areas, and US military personnel. 2 The diagnosis of VL is typically made by performing either bone marrow, liver, or splenic aspirate/biopsy and examining the tissue sample (by culture, microscopy, or polymerase chain reaction [PCR] assay) for the presence of Leishmania organisms. Recently, a significant advance in the diagnosis of VL has been developed, which allows for the rapid and non-invasive diagnosis of this condition.
The rK39 test (KalazarDetect; InBios, Seattle, WA; and DiaMed-IT LEISH; Cressier sur Morat, Switzerland) was developed from a recombinant antigen containing a 39 amino acid repeat found in Leishmania infantum-chagasi, part of a kinesin-related protein produced mainly by amastigotes. 3 The test has been developed in both an ELISA and immunochromatographic strip (dipstick) platform and is designed to detect antibodies against the rK39 antigen, which are produced in response to VL. Advantages of the assay include requiring only phlebotomy rather than invasive tissue sampling, the potential for a rapid turn-around time, and no requirement for an expert interpretation of the result.
The rK39 dipstick has been studied extensively, with a recent meta-analysis of 13 studies reporting an overall sensitivity and specificity of 94% and 91%, respectively, for the diagnosis of VL. 4 However, in some reports, the test showed cross-reactivity in patients with cutaneous leishmaniasis (CL), with up to 20% of CL patients having a positive rK39 dipstick result. [4] [5] [6] [7] Because these studies were conducted in geographic locales endemic for both CL and VL Leishmania syndromes, it is uncertain whether the detection of anti-rK39 antibodies in patients with active CL represents antibodies produced in response to active tegumentary infection or whether the positive assay represents sub-clinical VL or perhaps prior episodes of CL and/or VL.
With the advent of Operations Iraqi Freedom (Iraq) and Enduring Freedom (Afghanistan), the Walter Reed Army Medical Center (WRAMC) has evaluated and treated > 500 patients with Old World CL. Most of these patients had never previously lived or traveled to Leishmania-endemic regions of the world and thus represented a unique cohort in which to evaluate the prevalence of positive rK39 assays in a heretofore Leishmania-naive population.
MATERIALS AND METHODS
Seventy-three frozen serum samples collected from participants enrolled in an ongoing Leishmania developmental diagnostics protocol were used for this study. Serum samples represented 59 active cases of confirmed (by culture, microscopy, and/or real-time PCR) CL, 3 cases of VL, and 11 control samples. Leishmania species identification was performed for CL and VL patients either by glucose phosphate isomerase (GPI)-based RT-PCR, which has been previously described, or by cellulose acetate electrophoresis (CAE) of cultured promastigotes. 8, 9 The CL and VL patients were previously healthy American soldiers referred to WRAMC, Washington, DC, for treatment. Controls were otherwise healthy, generally young men, with no exposure history to Leishmania including no travel to Leishmania-endemic regions. Associated demographic, clinical, and microbiologic information was available for all collected sera. All CL patients whose serum was used in this study underwent subsequent treatment with sodium stibogluconate and were assessed with daily clinician visits and frequent laboratory analyses for at least 2 weeks (with no evidence of visceral infection) and then followed for up to 1 year. Both the current project and the diagnostics protocol were approved by the Institutional Review Boards at the investigators' institutions.
Serum samples were thawed once, and both the Kalazar DetectELISA (InBios) and Kalazar Detect Rapid Test (InBios) were performed on each test in accordance with the manufacturer's directions. For the ELISA, samples were run in duplicate, and a result was considered positive when the optical density (OD) exceeded 0.19 (mean from the negative controls plus three times the SD).
Statistical analysis was completed using SPSS statistical software, version 12.0.1 (SPSS, Chicago, IL). Demographic variables at baseline were compared using the Mann-Whitney test and Fisher exact tests to determine differences that existed between CL patients with positive and negative rK39 test results. P < 0.05 was considered statistically significant.
RESULTS
Using the rK39 dipstick, six CL patients (10.2%; 95% CI: 4-21%) and all three VL patients tested positive. Using the ELISA assay, the 6 patients with positive dipstick results, the 3 VL patients, and an additional 17 CL patients with negative dipstick results tested positive (28.8%; 95% CI: 18-42%). The 11 control and remaining CL patients (N ‫ס‬ 36) had negative rK39 ELISA assays and dipstick results (Figure 1) .
The demographic and clinical characteristics of the study patients are listed in Table 1 
DISCUSSION
In this first study to examine the test characteristics of the Leishmania rK39 dipstick assay in US patients with CL, 10% of patients tested positive using the dipstick assay and 29% with the ELISA format. This rate is similar to the rates of positive assays reported in previous studies conducted in Leishmania-endemic locales. [5] [6] [7] ELISA was more sensitive in our study, which is consistent with previous reports as well. 10 Previous studies have suggested that positive rK39 test results in patients with CL could represent incubating or previous VL infection by L. L. infantum-chagasi. 10, 11 One study reported that in contacts of patients with VL, 69% of those initially asymptomatic with a positive rK39 assay developed VL within 1 year. 11 It is unlikely that our patients had subclinical VL infection because there have been very few cases of VL diagnosed in our general patient population and none of the current cohort of CL patients had clinical evidence of a systemic infectious process. 2 Although the possibility of subclinical VL infection cannot be totally excluded based on our methods, we believe that our results support the notion that CL itself (infection by L. L. major) rather previous or incubating VL can cause a positive rK39 assay.
Besides leishmaniasis, positive rK39 assay results have been reported in patients with malaria, Chagas disease, tuberculosis, leprosy, and African trypanosomiasis. 5, 12 None of the patients in this study had evidence of these infections at the time of diagnosis or during the year of follow-up. It is unlikely that cross-reactivity from one of these infections caused their positive rK39 assay.
Univariate analysis showed that patients with more lesions and larger lesions were more likely to have positive rK39 test results. The association between number and size of lesions and a positive rK39 dipstick result makes intuitive sense and suggests that a greater parasitologic burden results in antibody production rising to the limits of detection by the rK39 assay. These results are supported by an earlier study in CL patients that reported increasing antibody titers with increasing lesion size. 13 Travel history to the Iraq and Afghanistan was also associated with positive tests; however, it is likely that these results were based on the large size of lesions from patients in Afghanistan. There were too few patients from each travel location to perform further multivariate analysis.
In conclusion, this study showed that, in a cohort of North American patients infected with CL, 10% will have a positive rK39 dipstick test. Patients with larger lesions and more lesions were more likely to have a positive result. A positive rK39 assay result is not always indicative of VL, and positive results should be interpreted with caution in patients who are at risk for or have CL or those without classic VL symptoms. These patients may deserve further monitoring or diagnostic evaluation to better determine the etiology of their positive test. In patients who are suspected of having VL (the population for which the test was developed), the rK39 assay has performed well diagnostically, and our results should not change the current practice of those who use the test in this setting.
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